Last reviewed · How we verify

NCT02461706: Cannabidiol

Treatment of Drug Resistant Epilepsy

NO LONGER AVAILABLE Last updated 22 January 2019
What this trial tests

trial testing cannabidiol in Epilepsy. No longer available.

Quick facts

Lead sponsorUniversity of Florida
StatusNO LONGER AVAILABLE
Study typeEXPANDED_ACCESS
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Florida

Who can join

Adults 2 to 16, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main goal of this study is to provide treatment with cannabidiol (CBD) to children with drug resistant epilepsy through a Physician Expanded Access Investigation New Drug protocol. As the controlled therapeutic use of CBD in children is novel, the primary objective of this study is to evaluate the safety and efficacy of CBD when administered as adjunctive therapy in children that have exhausted the majority of FDA approved antiepileptic drug treatment options.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
    Silvestro S, Mammana S, Cavalli E, Bramanti P, et al · · 2019 · cited 114× · PMID 31013866 · DOI 10.3390/molecules24081459
  2. Cannabinoids in Pediatrics.
    Campbell CT, Phillips MS, Manasco K. · · 2017 · cited 39× · PMID 28638299 · DOI 10.5863/1551-6776-22.3.176

Verify or expand the search:

Other trials of cannabidiol

Trials testing the same drug.

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

Other University of Florida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02461706.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing